Ocuphire Pharma Hits New 52-Week High of $5.09, Up 187.65%

Ocuphire Pharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 5.09 on March 6, 2026. This achievement marks a remarkable increase in the stock's performance, showcasing a 187.65% rise over the past year, significantly outpacing the S&P 500's 17.45% gain during the same period. As a microcap company in the Pharmaceuticals & Biotechnology sector, Ocuphire Pharma has a market capitalization of USD 234 million. Despite its impressive stock performance, the company remains in a loss-making position, with a negative price-to-earnings ratio and a return on equity of -577.66%. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. The stock's journey from a 52-week low of USD 0.65 to its current high reflects notable volatility and investor sentiment within the biotechnology space. As Ocuphire Pharma continues to navigate its market position, this new high underscores the dynamic nature of its stock performance.